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Abstract
Herpes simplex virus type 1 variants selected by virus propagation in cultured cells in the presence of the sulfated oligosaccharide PI-88 were
analyzed. Many of these variants were substantially resistant to the presence of PI-88 during their initial infection of cells and/or their cell-to-cell
spread. Nucleotide sequence analysis revealed that the deletion of amino acids 33–116 of gC but not lack of gC expression provided the virus with
selective advantage to infect cells in the presence of PI-88. Purified gC (Δ33–116) was more resistant to PI-88 than unaltered protein in its binding
to cells. Alterations that partly contributed to the virus resistance to PI-88 in its cell-to-cell spread activity were amino acid substitutions Q27R in
gD and R770W in gB. These results suggest that PI-88 targets several distinct viral glycoproteins during the course of initial virus infection and
cell-to-cell spread.
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The ability of sulfated polysaccharides and other polysulfo-
nated compounds to inhibit infection of cells by herpes simplex
virus (HSV) is a long known phenomenon (Vaheri, 1964).
These compounds are structurally related to cell surface heparan
sulfate (HS) receptor for attachment of HSV to cells (WuDunn
and Spear, 1989) and seem to act by competing with HS chains
for binding to the virus component(s) (Vaheri, 1964; WuDunn
and Spear, 1989). Glycoproteins gC, gB and gD of HSV type 1
(HSV-1) envelope have been reported to interact with heparin/
HS chains (Herold et al., 1991; Tal-Singer et al., 1995; Shukla et
al., 1999; Trybala et al., 2000) and these components therefore
represent the likely targets for sulfated polysaccharide inhibi-
tors. Indeed, sulfated polysaccharides were shown to inhibit
HSV attachment to cells (Vaheri, 1964; WuDunn and Spear,
1989), a step in the HSV–cell interaction mediated by⁎ Corresponding author. Fax: +46 31 827032.
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doi:10.1016/j.virol.2007.05.040glycoproteins gC and/or gB (Herold et al., 1991, 1994). It is
unclear whether or not sulfated polysaccharides could interfere
with virus entry into cells. Although this step can be initiated by
interaction of HSV-1 gD with specific 3-O-sulfated chains of
HS (Shukla et al., 1999), this glycoprotein can also interact with
TNF-receptor like protein (Montgomery et al., 1996) or nectin
(Geraghty et al., 1998) to trigger virus entry into cells.
The antiviral potential of sulfated polysaccharides usually
increases with increasing sulfation and chain length, however,
low molecular weight and extensively sulfated oligosaccharides
also exhibit antiviral properties (Witvrouw and De Clercq,
1997). PI-88 is a low molecular weight sulfated oligosaccharide
in clinical development as an anticancer drug that also shows
anti-HSV (Nyberg et al., 2004), anti-dengue and -encephalitic
flavivirus (Lee et al., 2006), and anti-malarial (Adams et al.,
2006) activities. Structurally, PI-88 is a mixture of highly
sulfated mannose di- to hexasaccharides. Thus, compared with
heparin PI-88 is composed of shorter but more extensively
sulfated oligosaccharides. In our previous work (Nyberg et al.,
2004) we have found that PI-88 reduced the cell-to-cell spread
Fig. 1. The PI-88 resistant plaque variants of HSV-1. (A) PI-88 resistant (large)
and sensitive (small) plaque variants of HSV-1 gC−39 strain. (B) PI-88 resistant
(large and syncytial) and sensitive (small and syncytial) plaque variants of HSV-
1 MP strain.
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of PI-88 resistant variants in the gC-negative strains of HSV-1
suggested that viral components other than gC could be targeted
by PI-88 during the course of viral infection of cells. The
development of HSV-1 variants resistant to the sulfated
polysaccharides carrageenan (Carlucci et al., 2002) or heparin
(Goodman and Engel, 1991; Pertel and Spear, 1996) has been
reported, however, except for gK (Pertel and Spear, 1996),
nucleotide sequences of genes coding for other relevant viral
components were not analyzed. In this work, we attempted to
elucidate the molecular basis for the resistance of HSV-1
variants to PI-88. Our study demonstrated that the deletion of
amino acids 33–116 of gC but not lack of gC expression
provided the virus the ability to infect the cell in the presence of
PI-88 while specific alterations in gB or gD partly promoted the
PI-88 resistant cell-to-cell spread of HSV-1.
Results and discussion
PI-88 escape variants of HSV-1
In our previous work we found that, compared with heparin,
PI-88 inhibited the initial infection of cultured cells with HSV
less efficiently but reduced the cell-to-cell spread of the virus
more profoundly (Nyberg et al., 2004). Here we repeated this
experiment with different strains of HSV. The effect of PI-88 on
the cell-to-cell spread activity of HSV, measured as a reduction
in the size of HSV plaques developed in GMK AH1 cells in the
presence of PI-88 in an overlay medium, is shown in Table 1.
PI-88 reduced the size of plaques developed by all HSV-1 and
HSV-2 strains tested. During this investigation we noticed the
presence of relatively large PI-88 resistant plaques that occurred
in the HSV-1 gC-null/negative strains (Fig. 1). This observation
suggesting that alteration in viral component(s) other than gC
can be responsible for PI-88 resistant cell-to-cell spread of HSV-
1 encouraged us to prepare PI-88 escape variants of the virus
and to investigate molecular basis for their drug resistance.
The gC-proficient HSV-1 KOS strain (not KOS321) was
chosen for our attempts to isolate PI-88 resistant variants of the
virus. To this end, the plaque purified virus (KOSc) was
subjected to ten passages in GMK AH1 cells in the presence of
PI-88. The KOSc strain, passaged under similar conditions in theTable 1
Effect of PI-88 oligosaccharides on plaque size of HSV strains in GMK AH1
cells
Virus Average plaque area (mm2, n=20) % of
control
PI-88 (100 μg/ml) Control
HSV-1 17syn+ 0.058±0.025 0.188±0.074 30.5 a
HSV-1 2762 0.041±0.018 0.154±0.041 26.3 a
HSV-1 KOS 0.033±0.029 0.115±0.077 28.7 a
HSV-1 KOS321 0.043±0.018 0.209±0.071 20.6 a
HSV-1 gC−39 (gC-null) 0.041±0.043 0.162±0.078 25.4 a
HSV-1 MP (gC-negative) 0.059±0.029 0.494±0.157 12.0 a
HSV-2 333 0.028±0.011 0.318±0.211 8.9 a
HSV-2 gCneg1 (gC-negative) 0.047±0.018 0.478±0.136 9.8 a
a Statistically significant differences at P values of b0.001.absence of PI-88 (KOSc passage 10), served as control material.
The virus was exposed to PI-88 throughout its propagation in
cells, i.e., during the virus attachment to and entry into the cells
and its subsequent spread via released and cell-to-cell trans-
mitted progeny virus. The viral plaque variants (AC variants)
that survived the selective pressure from PI-88 were immunos-
tained with monoclonal anti-gC-1 antibody which revealed that
46.6% of them had the gC-negative phenotype. Approximately
1.5% of AC variants formed syncytial plaques of which
approximately 50% were gC-negative.
To verify the PI-88 resistant phenotype of AC variants as
well as to identify possible genotypic alterations, six AC
variants were plaque purified and then tested for sensitivity to
PI-88 (Table 2). The gC-positive variants (AC1 through AC4)
but not the gC-negative (AC5, AC6) ones were 6–12 times
more resistant than parental KOSc strain to PI-88 in the plaque
number reduction assay, a procedure in which the virus was
exposed to PI-88 during initial infection of cells only. To verify
the possibility that AC1–AC4 mutants may bind to cells in the
presence of PI-88 and then infect them when PI-88 is removed,
these variants were retested in the plaque number reduction
assay that included the step of washing the cells with the low pH
buffer. The results of this assay and the original plaque number
Table 2




gC Syncytium Plaque number reduction
assay b IC50 (μg/ml)
Plaque number reduction assay,
pH 3 c IC50 (μg/ml)
Plaque size reduction assay d
% of control area
KOSc + − 8.3 9.1 27.5 (0.205)
KOSc (passage 10) + − 6.0 NT 19.7 (0.094)
AC1 + − 48 60 53.5 (0.255)
AC2 + − 58 70 67.7 (0.304)
AC3 + + N100 N100 70.6 (1.750)
AC4 + − 47 42 50.6 (0.299)
AC5 − +/− 4.0 4.7 50.0 (0.274)
AC6 − − 4.6 5.1 44.7 (0.250)
A1 − + 2.8 5.1 14.2 (0.278)
A2 + + 3.6 1.8 15.0 (0.815)
A3 + + 5.1 5.3 10.7 (0.338)
A4 − − 3.0 4.2 20.7 (0.101)
A5 + − 8.0 2.2 24.9 (0.238)
C1 + − 7.0 2.5 53.4 (0.306)
C2 + +/− 11.0 7.0 58.7 (0.262)
C3 + − 8.5 2.5 42.9 (0.262)
gC−39-S − − 1.2 NT 16.5 (0.068)
gC−39 R6 − − 2.4 NT 57.6 (0.197)
MP-S − + 16 NT 14.0 (0.633)
MP R15 − + 15 NT 59.6 (1.801)
gC−39-S+AC3gC e + − 30 NT 20.7 (0.039)
KOSc+AC3gDe + − 9 NT 38.1 (0.168)
KOSc+A1gKe + + NT NT NT
gC−39-S+R6gDe − − 1.6 NT 62.5 (0.118)
MP-S+R15gB e − + 7 NT 55.2 (0.980)
a Variants selected for by the PI-88 presence limited to either initial infection of cells (A1–A5) or spread of progeny virus (C1–C3; gC−39 R6; MP R15) or both
(AC1–AC6).
b Serial PI-88 dilutions were incubated with ∼200 PFU of the virus for 10 min prior to and during a 2 h period of infection of GMK AH1 cells at 37 °C. Results are
expressed as a concentration of PI-88 that reduced the number of viral plaques by 50%.
c Assay performed as per plaque number reduction assay except that the cells were washed with citrate-buffered saline, pH 3.0, at the end of a 2 h period of virus
infection of cells.
d PI-88 (100 μg/ml) in an overlay methylcellulose mediumwas added to cells after their infection with the virus and incubated with cells throughout the development
of viral plaques. Results are expressed as a percentage of the average area of 20 viral plaques developed in the presence of PI-88 medium relative to mock-treated
controls. Shown in parentheses is the average area (in mm2) of 20 viral plaques developed in the absence (control) of PI-88.
e Viruses prepared by the molecular transfer of specific gene fragments into DNA of parental strains KOSc, gC−39-S or MP-S.
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AC4 variants can efficiently infect the cells in the presence of
PI-88. In the plaque size reduction assay, both gC-positive and
gC-negative AC variants were more resistant to PI-88 than
KOSc (Table 2).
We sought to identify the alteration(s) in viral variants
responsible for PI-88 resistant phenotype based on the reason-
ing that the viral component(s) involved may provide, in their
wild-type form, the potential binding sites for HS and for the
HS-mimetic compounds. Nucleotide sequence analysis of genes
coding for the known HS-binding proteins gB, gC, gD and the
syncytium-modulating protein gK is shown in Table 3. Variants
AC1–AC4, which exhibited substantial resistance to PI-88 both
in their initial infection of cells and the cell-to-cell spread, all
carried the large deletion of amino acids 33–116 of gC (Table
3). Variant AC3, the most resistant to PI-88 (Table 2), had also
the Q27P amino acid substitution in gD, and the syncytium-
inducing R828H alteration in the endodomain of gB (Table 3).
The latter mutation also occurs in HSV-1 HFEMtsB5 (Bzik et
al., 1984) and HSZP (Kosovsky et al., 2000) strains. The second
most PI-88 resistant variant AC2 had, in addition to gC change,two mutations in the gB ectodomain. Variants AC5 and AC6
were gC-negative due to the frameshift in the gC gene caused by
the deletion of a single nucleotide, and the latter variant also
contained the Q27P substitution in gD (Table 3). Both these
variants were partly resistant to PI-88 in the plaque size but not
the plaque number reduction assay (Table 2). The lack of gC
expression is unlikely to contribute to this phenotype since the
gC−39 strain (gC-null) was sensitive to PI-88 (Tables 2 and 3).
Hence, mutation found in gD (AC6) or in an unsequenced gene
(AC5) may account for the PI-88 resistant cell-to-cell spread of
these variants (see the next chapter of this section).
HSV-1 variants generated under similar experimental
conditions as AC variants based on their resistance to other
sulfated oligo/polysaccharides, i.e., heparin (Goodman and
Engel, 1991) or carrageenan (Carlucci et al., 2002), have been
described. Heparin resistant variants of HSV-1 were selected for
by five virus passages in rabbit skin cells in the drug presence.
Approximately 5% of selected virus formed syncytial plaques
and this phenotype was due to the A825V substitution in gB
endodomain (Goodman and Engel, 1991; Engel et al., 1993).
Likewise, HSV-1 generated by sixteen passages in the presence
Table 3




gC Syncytium gB gC gD gK
AC1 + − – Δg96-g347 – –
ΔP33-G116




AC3 + + g2573a Δg96-g347 a155c –
R828H ΔP33-G116 Q27P
AC4 + − – Δg96-g347 c89t –
ΔP33-G116 A5V
AC5 − +/− – Δc264 – –
Frameshift
AC6 − − – Δc264 a155c –
Frameshift Q27P
A1 − + – Δc366 – c973a
Frameshift L325I
A2 + + – g452a – c973a
R151H L325I
A3 + + c2289t – – c973a
Silent L325I
A4 − − c2289t Δc366 – c67t
Silent Frameshift L23F
A5 + − – – – –
C1 + − – g452a – –
R151H
C2 + +/− – – c938t g853a
P288L A285T
C3 + − – g752a – c492t
S251N Silent




MP R15 − + c2386t NT – –
R770W
a Variants selected for by PI-88 presence limited to either initial infection of
cells (A1–A5) or spread of progeny virus (C1–C3; gC−39 R6; MP R15) or both
(AC1–AC6).
b Nucleotide and predicted amino acid alterations are denoted with lowercase
and uppercase letters respectively. Nucleotide numbering begins from the first
nucleotide of the initiation codon. Amino acid numbering in gC and gK begins
from the initiation methionine while that in gD and gB from the first amino acid
of the mature protein. The GenBank accession numbers are: EF157309 for AC2
gB, EF157310 for AC3 gB, EF157311 for A3 gB, EF177452 for gC−39-S gB,
EF177453 for gC−39 R6 gB, EF177454 for MP-S gB, EF177455 for MP R15
gB, EF157313 for AC1-4 gC, EF157314 for AC5,6 gC, EF157315 for A1 gC,
EF157317 for A2,C1 gC, EF157318 for C3 gC, EF157320 for AC3,6 gD,
EF157321 for AC4 gD, EF157322 for C2 gD, EF177450 for gC−39-S gD,
EF177451 for gC−39 R6 gD, EF157324 for A1–3 gK, EF157325 for C2 gK and
EF157326 for C3 gK. All other sequences of AC, A and C variants were
identical to those of parental strain KOSc gB (EF157316), KOSc gC
(EF157312), KOSc gD (EF157319) and KOSc gK (EF157323).
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likely alteration(s) in gB was suggested as responsible for
syncytial phenotype. However, possible adaptative alterations
in other viral components of these heparin or carrageenan
resistant variants of HSV-1 were not investigated.
Knowing that some of the AC variants exhibited resistant
phenotypes both in their initial infection of cells and the cell-to-cell spread, we asked whether limitation of selective pressure
from PI-88 to one of these steps would select for the distinct
HSV-1 variants. To this end, the plaque purified virus (KOSc)
was subjected to ten passages in GMK AH1 cells, and the
presence of PI-88 was limited to the step of initial virus infection
of cells (variants A). Analysis of uncloned virus revealed that
61.2% of plaque variants A had the gC-negative phenotype, and
2.3% formed syncytial plaques in GMK AH1 cells. Approxi-
mately 0.7% of plaque variants had both gC-negative phenotype
and syncytial plaque morphology. Several of these variants were
plaque purified and then tested for their sensitivity to PI-88.
None of variants A (Table 2) including gC-negative ones (A1,
A4) were resistant to PI-88 in both the plaque number and the
plaque size reduction assays as their sensitivities to this
compound were comparable to or even somewhat greater than
that of the parental KOSc or KOSc (passage 10) strain. A
possibility that putative PI-88 resistance was lost during plaque
purification of variants A is unlikely because the drug resistant
AC variants were plaque purified in an identical manner.
Moreover, PI-88 at a concentration used in selection experiments
(100 μg/ml) decreased the number of plaques developed by
parental KOSc and all variants A by approximately 94–98%
(data not shown), thus further confirming their PI-88 sensitive
phenotype. Genotypic alterations in variants A were mainly
detected in gC and gK genes. Of these, variants A1 and A4 were
gC-negative due to the frameshift in the gC gene while A2
exhibited a single R151H amino acid substitution in this protein.
The syncytium-inducing activity of variants A1–3 was due to
the L325I alteration in gK (Table 3). This is a novel syncytium-
inducing mutation in gK, confirmed by the marker transfer
experiment (Table 2, KOSc+A1gK variant). In the model of
HSV-1 gK membrane topology (Foster et al., 2003) this
mutation occurs within a transmembrane region that separates
domains III and IVof this protein. Note that syncytium-inducing
mutants, which as mentioned above account for only 2.3% of all
variants A, are overrepresented in Table 3. Therefore the
incidence of syncytium-inducing mutations in gK of variants A
may in fact be much lower than that suggested by our data.
Variant A5 lacking alterations in analyzed genes (Table 3) may
have survived selective pressure from PI-88 accidentally or it
may contain mutation in an unsequenced gene. These results
suggest that when the selective pressure from PI-88 is limited to
initial virus infection of cells, a high proportion (61.2%; see
above) of the gC-negative variants is, among other mutants,
selected for. However, this phenotype is not sufficient to render
the virus resistance to PI-88.
Pertel and Spear (1996) analyzed variants of HSV-1
generated by virus passage in HEp-2 cells with selective
pressure from the sulfated polysaccharide heparin limited to
initial virus infection of cells, i.e., under experimental
conditions similar to those used for the PI-88-forced selection
of variants A. Although the proportions of the gC-negative
variants were comparable when heparin (Pertel and Spear,
1996) or PI-88 (this report) was used as a selective drug, the vast
majority of heparin variants formed syncytia in cultured cells
(Pertel and Spear, 1996) while only a minor fraction of PI-88
selected variants had this phenotype. It is unclear whether this
248 M. Ekblad et al. / Virology 367 (2007) 244–252difference was due to the fact that we used plaque purified HSV-
1 KOS strain in the selection experiments. More importantly,
analysis of heparin resistant virus variants revealed that the
absence of gC was sufficient to confer HSV-1 resistance to
heparin and that syncytium-inducing mutations in gK augmen-
ted these effects by enhancing the lateral spread of HSV-1 in
cultured cells (Pertel and Spear, 1996). As mentioned above, we
found that although more than 60% of plaque variants had the
gC-negative phenotype and one of the mutants carried an
alteration in the putative attachment domain of gC (Mardberg et
al., 2001), these variants did not appear to be resistant to PI-88.
While we have no explanation for this difference, we noticed
that PI-88, in contrast to heparin (Pertel and Spear, 1996),
inhibited infection of GMK AH1 cells by the gC-negative
variants and strain gC−39 more effectively than that of the gC-
proficient parental strain (Table 2). This suggests that, apart
from gC, PI-88 can efficiently target another viral component
involved in the initial HSV–cell interaction. Consequently none
of variants A appeared to be resistant to PI-88, and possibly a
greater number of virus passages or continuous presence of PI-
88 may be required to select for the drug-resistant variants of
HSV-1.
We also analyzed variants of HSV-1 KOSc strain generated
by virus passage in GMK AH1 cells with the presence of PI-88
limited to the spread of viral infection via released extracellular
and cell-to-cell transmitted virus (Table 2, variants C). None of
variants C had the gC-negative phenotype, and approximately
0.7% formed syncytia in cultured cells. Variants C1, C2 and C3
exhibited similar sensitivity to PI-88 as the parental KOSc strain
in the plaque number reduction assay (Table 2). However, these
mutants showed partial resistance to PI-88 in the plaque size
reduction assay. Although C1 and C3 variants carried specific
amino acid substitutions in gC, none of C variants (Table 3)
including those present in the original mixture of the drug-
selected mutants (see above) appeared to be gC-negative. This
suggests that gC is less extensively targeted by PI-88 during the
cell-to-cell spread of HSV-1 than the initial infection of cells with
free virus. Variant C2 had the P288L substitution in amembrane-
proximal proline-rich stalk of gD. In the crystal structure of
native gD, this region of the protein was found to anchor near the
N-terminally located domain that comprises residues L25–Q27
(Krummenacher et al., 2005). It has been proposed that, upon
receptor binding, the C-terminal region is released from this
“closed” conformation of gD, a change that triggers HSV-1 entry
into the cell (Fusco et al., 2005; Krummenacher et al., 2005).
Note that mutations detected in variants C occurred in different
viral components, and our attempts to verify their importance for
the observed phenotype in the marker transfer experiments were
unsuccessful (Table 2). Therefore, one cannot exclude that
mutation in an unsequenced gene may confer the virus resistance
to PI-88 in its cell-to-cell spread. Included in Table 2 are also two
plaque variants of HSV-1 gC-negative strains (Fig. 1) that, like
variants C, were generated by selective pressure from PI-88
limited to the cell-to-cell spread of the virus, where a single virus
passage in cells was sufficient. These variants occurred at
frequencies of 9.3% for non-syncytial gC−39 and 2.2% for the
syncytium-forming MP strain. The PI-88 resistant variantsgC−39 R6 and MP R15 as well as PI-88 sensitive parental
viruses gC−39-S andMP-Swere plaque purified to homogeneity
and then retested in the plaque size and plaque number reduction
assays for their sensitivity to PI-88. As expected, the presence of
PI-88 (100 μg/ml) in an overlay medium reduced the plaque area
of parental strains gC−39-S or MP-S by N80% while those of
gC−39 R6 or MP R15 by ∼40% (Table 2). Thus, these plaque
variants of HSV-1 appeared to be substantially, but not
completely, resistant to PI-88. Note also that in the absence of
PI-88 these variants produced larger plaques than their
respective parental strains (Table 2). Interestingly, in contrast
to the results of the plaque size reduction assay, the PI-88-
selected variants showed either comparable or ∼2-fold higher
resistance to PI-88 than parental strains in the plaque number
reduction assay (Table 2). These results suggest that the relative
PI-88 resistance of variants C as well as plaque variants gC−39
R6 and MP R15 was mainly due to decreased drug sensitivity of
their cell-to-cell spread capability rather than the initial infection
of cells by these viruses.
The gC−39 R6 carried two mutations in gB one of which
predicted the T474A amino acid substitution (Table 3). Because
alanine at position 474 is also present in gB of the PI-88
sensitive strains KOS (EF157316) and KOS321 (Robbins et al.,
1987), this mutation is unlikely to confer the drug resistance of
gC−39 R6. This viral variant was also altered in the gD
component displaying Q27R amino acid substitution. Since the
parental gC−39 strain contains the L25P amino acid substitution
as compared to the wild-type gD sequence of KOS strain
(Watson et al., 1982), this mutation in gD also occurs in gC−39
R6 variant. Thus, the gC−39 R6 carries the same mutations in
the amino-terminal part of gD as HSV-1 ANG strain (Lingen et
al., 1995). Because ANG strain was isolated by using a protocol
similar to that described for gC−39 R6 (the presence of natural
sulfated oligo/polysaccharides in an agar overlay) (Munk and
Ludwig, 1972), it is likely that isolation of viral variants altered
at specific viral genes can, to some extent, be related to the
presence of sulfated inhibitor during specific stage of viral
infection of cells. The MP R15 plaque variant contained the
R770W amino acid substitution in the membrane-proximal
region of the gB endodomain (Table 3), a change previously
identified as a syncytium-inducing mutation (Gage et al., 1993).
This variant produced larger syncytial plaques than the parental
MP strain. However, it is noteworthy that the size of plaques
developed by parental MP strain, which forms syncytia by itself
due to alteration in gK (Pogue-Geile and Spear, 1987), was
greatly reduced by PI-88 (Table 2) suggesting that specific
alteration(s) in gB but not in gK rendered the virus spread in
cultured cells resistant to PI-88.
Contribution of specific alterations to the PI-88 resistant
phenotypes of HSV-1
To investigate importance of specific mutations for the PI-88
resistant phenotype of HSV-1, the DNA fragments comprising
part or entire sequence of gB, gC, gD or gK gene were mixed
with DNA purified from parental strain KOSc, gC−39-S or MP-
S and co-transfected into GMK AH1 cells. A list of alterations
Fig. 2. The effect of PI-88 on binding to cells of purified HSV-1 virions or HSV-
1 glycoproteins. PI-88 at different concentrations was incubated with purified
3H-thymidine labeled virions of HSV-1 KOSc, AC1 or AC5 variant (A) or
isolated glycoproteins gC (B) or gB (C) of KOSc, AC2 or AC3 variant for
15 min prior to and during 1–2 h period of virus or glycoprotein adsorption to
GMK AH1 cells. The results are shown as a percentage of attached viral cpm, or
absorbance of cell-bound viral glycoprotein detected with PI-88 treated samples
relative to mock-treated controls. Values shown are means of four determina-
tions from two separate experiments.
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shown in Table 2. Glycoprotein C gene of PI-88 resistant
variants AC1–AC4 that contains a large deletion of 252
nucleotides was successfully transferred into the background of
gC-null strain gC−39-S. Analysis of the resulting mutant
gC−39-S+AC3gC (Table 2) revealed that this alteration in gC
conferred the virus resistance to the presence of PI-88 during
initial infection of cells but not during the cell-to-cell spread of
HSV-1 (Table 2). The deleted segment of gC gene codes for
amino acids 33 through 116 at the amino terminal part of gC
protein. This region has been reported to promote HSV-1
attachment to cells (Tal-Singer et al., 1995). Due to the presence
of numerous O-and N-glycosylation sites, this fragment of gC
forms a mucin-like structure, and it would be of interest to
determine how PI-88 could interact with such moiety. It is also
noteworthy that variants with this specific deletion in gC but not
the gC-negative ones appeared to be resistant to PI-88 (Table 2).
To clarify this issue, purified radiolabeled virions of AC1
(Δ33–116), AC5 (gC-negative) or KOSc were tested for their
ability to attach to cells in the presence of PI-88 (Fig. 2A). AC1
variant was less efficiently than AC5 or KOSc inhibited by PI-
88. Note that similar tendencies were observed when these
viruses were examined in the plaque number reduction assay
(Table 2). Likewise, truncated gC purified from variants AC2 or
AC3 was less efficiently than gC of KOSc strain inhibited by
PI-88 in the cell-binding assay (Fig. 2B). One explanation of
these data could be that absence of entire gC may activate/
expose a redundant attachment domain or PI-88 sensitive site in
another viral protein while the presence of truncated gC may
block this domain or inefficiently compete with it for binding to
PI-88. Generation of additional PI-88 resistant variants of HSV-
1 gC-negative viruses may help to identify this putative domain.
In contrast to the AC1–4 variants where alteration in sole
viral component (gC) conferred resistance to PI-88 in their initial
infection of cells, many mutants resistant to PI-88 in the cell-to-
cell spread activity (AC1–6; C1–3) contained occasional
changes in gB, gC, gD and/or gK. This suggests that specific
alterations in different viral components can, to some extent,
contribute to the virus resistance in the cell-to-cell spread or that
a mutation in an unsequenced gene may confer resistance. The
Q27R alteration, identified in gD of variant gC−39 R6, and
successfully transferred into gC−39-S+R6gD mutant, rendered
its cell-to-cell spread but not initial infection of cells relatively
resistant to PI-88 (Table 2). However similar alteration (Q27P)
found in AC3 and AC6 variants and transferred into the gC-
proficient KOSc strain caused only partial resistance to PI-88 in
the cell-to-cell spread activity (Table 2) suggesting that presence
of gC may influence functions of gD. It was reported that the
heparin resistant variants of HSV-1, which as mentioned above
were altered in gC and gK, exhibited partial resistance to gD-
mediated interference (Pertel and Spear, 1997). HSV-1 gD can
interact among other cellular receptors also with nectin, a
component of adherens junctions. It was reported that mono-
clonal anti-nectin-1 antibody reduced cell-to-cell spread of HSV-
1 (Cocchi et al., 2000) further confirming essential role of gD in
this process. The Q27R, Q27P or L25P amino acid substitutions
in gD are known to confer both resistance of superinfectingHSV-1 to gD-mediated interference (Campadelli-Fiume et al.,
1990; Dean et al., 1994) and HSV-1 entry into the cells via the
nectin-2 receptor (Warner et al., 1998; Lopez et al., 2000; Yoon
et al., 2003). Interestingly ANG strain, which contains L25P and
Q27R alterations in gD, formed larger plaques in cells
expressing nectin-2 than in cells producing nectin-1 (Delboy et
al., 2006). This suggests that viruses with these alterations in gD
may exhibit enhanced entry and cell-to-cell spread activities thus
escaping selective pressure from PI-88 inhibitor. The L25P and
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binding of gD to 3-O-sulfated forms of HS (Yoon et al., 2003)
suggesting that PI-88 can interfere with these interactions.
However, it is uncertain whether resistance of HSV-1 cell-to-cell
spread activity to PI-88 was due to usage of nectin-2 receptor or
abrogated virus interaction with 3-O-sulfated HS. The reason for
this is that the L25P substitution that alters receptor usage by
HSV-1 gD is present in the parental, PI-88 sensitive gC−39-S
strain (Table 2). Although this mutation had a less profound
effect on usage of gD receptors than did the Q27P/R substitution
(Yoon et al., 2003), its presence in the PI-88 sensitive virus
suggests that other explanations of the drug resistance pheno-
menon cannot be excluded.
We managed to transfer the R770W alteration, identified in
the gB component of MP R15 plaque variant, into parental strain
MP-S (Table 2; MP-S+R15gB variant). This specific alteration
in gB was required to escape the selective pressure from PI-88
during the cell-to-cell spread of HSV-1 (Table 2). We also
purified gB components from two PI-88 resistant variants (AC2
and AC3) and investigated their binding to cells in the presence
of PI-88 (Fig. 2C). Although gB components of both AC2 and
AC3 were somewhat less efficiently than KOSc gB inhibited by
PI-88, it is uncertain whether this little difference was due to
decreased affinity of mutated gB species for PI-88. Mutations in
the gB endodomain may alter expression of this protein at the
cell surface (Ruel et al., 2006) or induce distant conformational
change(s) in the gB ectodomain thus modulating its interaction
with cells. The recently reported crystal structure of HSV-1 gB
(Heldwein et al., 2006) reveals that the E244K alteration (AC2)
occurs in domain I of this protein that structurally resembles the
PH domain found in some phospholipid-binding cytoplasmic
proteins. It is also noteworthy that PI-88 selected for both
syncytium-inducing and non-syncytial variants of HSV-1
suggesting that the cell–cell fusion activity of the virus is not a
required feature to escape the antiviral effects of PI-88.
In conclusion, through analysis of PI-88 escape variants we
have found that this oligosaccharide inhibitor targeted two
distinct events which occur during initial HSV-1 infection of
cells and its cell-to-cell spread. Deletion of the mucin-like
region of viral gC conferred HSV-1 resistance to PI-88 in its
initial infection of cells while specific alteration in gB and gD
partly contributed to the PI-88 resistant cell-to-cell spread of the
virus. Given the fact that we have exposed the virus to strong PI-
88 selective pressure to generate these variants, and that the gC-
negative or syncytium-forming HSV-1 is only rarely isolated
from patients, PI-88, like other sulfated polysaccharides
(Witvrouw and De Clercq, 1997), could be regarded as a slow
and inefficient inducer of viral resistance.
Materials and methods
Cells, viruses and PI-88 oligosaccharide
African green monkey kidney (GMK AH1) cells (Gunalp,
1965) were cultivated in Eagle's minimum essential medium
(EMEM) supplemented with 2% fetal calf serum, 0.05%
Primaton RL substance (Kraft Inc., Norwich, CT, USA),100 U/ml of penicillin and 100 μg/ml of streptomycin. The
virus strains and mutants used were HSV-1 KOS (ATCC, VR-
1493), HSV-1 KOS321, a plaque purified isolate of wild-type
strain KOS (Holland et al., 1983), HSV-1 KOS gC-null strain
gC−39 (Holland et al., 1984), HSV-1 17syn+ (Brown et al.,
1973), HSV-1 2762 (Bergstrom and Lycke, 1990), HSV-1 gC-
negative and syncytium-inducing strain MP (Hoggan and
Roizman, 1959), HSV-2 strain 333 (Duff and Rapp, 1971) and
its gC-negative derivative designated HSV-2 gCneg1 (Trybala et
al., 2000). PI-88 was prepared as described previously (Yu et al.,
2002).
Preparation of PI-88 escape variants of HSV-1
HSV-1 strain KOS, which had been subjected to three rounds
of plaque purification, was used. The virus has been serially (ten
times) passaged in GMKAH1 cells in the presence of 100 μg/ml
of PI-88 according to three different protocols. (i) The virus was
incubated with PI-88 for 15 min prior to and during a 2 h period
of infection of GMK AH1 cells at 37 °C. The cells were then
washed with EMEM and incubated in fresh EMEM without PI-
88 until complete cytopathic effect (CPE) was observed. (ii) The
virus infection of cells took place at 37 °C for 2 h in the absence
of PI-88. The cells were then washed with EMEM and incubated
in EMEM supplemented with PI-88 until the development of
complete CPE. (iii) The virus was incubated with PI-88 for
15min prior to and during a 2 h period of infection of GMKAH1
cells at 37 °C. The cells were then washed with EMEM and
incubated in EMEM supplemented with PI-88 until the
development of CPE. After each passage the infectious culture
medium and infected cells were harvested and subjected to one
freeze–thaw cycle. Following centrifugation for 10 min at
1000×g, the supernatant medium was diluted in EMEM and
used for a subsequent passage. After the final passage, several
plaque variants from each group were subjected to three rounds
of plaque purification in the absence of PI-88.
Viral plaque assays
The plaque number reduction assay was carried out as
described previously (Ekblad et al., 2006; Nyberg et al., 2004).
For the plaque size reduction assay, monolayer cultures of
densely growing GMK AH1 cells were used. After a 2 h period
of virus infection of cells at 37 °C, the serum-free overlay
medium, composed of 1% methylcellulose solution in EMEM
and PI-88 (100 μg/ml), was added and incubated with cells
throughout the entire period of the development of viral plaques.
The images of 20 neighboring plaques were captured using a
DC300 digital camera (Leica, Heerbrugg, Switzerland) attached
to a Diavert microscope (Leitz-Wetzlar, Germany). Plaque area
was measured using IM500 image software (Leica, Cambridge,
UK).
Nucleotide sequencing
The preparation of HSV DNA and nucleotide sequencing of
the coding regions of gB, gC, gD and gK gene were performed
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al., 1999). The primers to be used in amplification and
sequencing reactions were designed based on the published
sequence of these genes in strain 17 (NC001806). The positions
of sense primers for HSV-1 gB gene were−71–(−52), 406–423,
773–790, 1116–1134, 1493–1512, 1731–1750, 2167–2184
and 2513–2530, and antisense primers 472–453, 870–849,
1186–1165, 1587–1570, 1899–1882, 2273–2256, 2587–2568
and 2854–2837. The positions of sense primers for HSV-1 gD
gene were −63–(−42), 330–350, 622–639 and 901–919, and
antisense primers 430–408, 727–708, 1020–1002 and 1335–
1317. The positions of sense primers for HSV-1 gC gene were
−152–(−132), 12–33, 318–338, 591–613, 813–833 and
1122–1144, and antisense primers 135–117, 392–373, 702–
681, 991–968, 1305–1283 and 1659–1639. The positions of
sense primers for HSV-1 gK were −95–(−78), 307–327 and
600–618, and antisense primers 395–375, 706–688 and 1057–
1039. All sequences were related to the original gene sequence
of cloned HSV-1 KOS strain (KOSc) from which the viral
variants were selected. In comparison with the published
sequences of HSV-1 KOS gB (AF311740), gC (J02216), gD
(J02217) and gK (U14422), KOSc possesses three nucleotide
changes in gB (cg938/9gc, a1544g), five in gC (t9g, g40a,
a899t, t1056c, c1070t), one in gD (a10g) and no alteration in gK
gene.
Marker transfer assay
HSV-1 DNAwas purified as described by Mettenleiter et al.
(1988). Specific sequences of viral DNA were amplified by
PCR using Pfu Turbo polymerase (Stratagene) and flanking
primers 1116–1134 and 2854–2837 for gB, −222–(−202) and
1880–1900 for gC, −63–(−43) and 1335–1317 for gD and
−95–(−78) and 1057–1039 for gK sequences. One microgram
of quantities of purified viral DNA and amplified viral sequence
in serum- and antibiotic-free EMEM was mixed with lipo-
fectamine 2000 reagent and incubated for 20 min at room
temperature. The mixture was added to a one-day-old culture of
GMK AH1 cells that reached ∼90% confluence at the day of
transfection. After incubation of cells for 5 h at 37 °C, the
medium was removed and fresh EMEM was added. In some
experiments EMEM was supplemented with 2% fetal calf
serum and PI-88 (100 μg/ml).
Binding of purified viral particles and viral glycoproteins to
cells
Methyl-3H-thymidine labeled extracellular virions of HSV-1
were purified by centrifugation through a three-step discontin-
uous sucrose gradient while HSV-1 glycoproteins gB and gC
were isolated from lysates of extracellular virions and virus-
infected cells by immunoaffinity chromatography as previously
described (Trybala et al., 2000). The binding or radiolabeled
HSV-1 virions to GMK AH1 cells in the presence of PI-88
inhibitor was assayed as previously described (Nyberg et al.,
2004) except for that PI-88 at specific concentrations in EMEM
was incubated with purified radiolabeled virus for 15 min priorto and during 2 h period of virus attachment to cells at 37 °C.
The binding of purified HSV-1 glycoproteins gB and gC to
GMK AH1 cells in the presence of specific concentrations of
PI-88 was assayed by an ELISA-based procedure as previously
described (Nyberg et al., 2004).
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